Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Braun, Vera ^a   Rempis, Eva ^a   Schnack, Alexandra ^a   Decker, Sarah ^a   Rubaihayo, John ^b   Tumwesigye, Nazarius Mbona ^c   Theuring, Stefanie ^a   Harms, Gundel ^a   Busingye, Priscilla ^d   Mockenhaupt, Frank P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MOUNTAINS OF THE MOON UNIVERSITY   (Uganda)

^c MAKERERE UNIVERSITY   (Uganda)

^d Holy Family Virika Hospital   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT;

ADULT; ALLELE; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE MUTATION; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NEWBORN MORTALITY; PFDHFR GENE; PFDHPS GENE; PLACENTA; POLYMERASE CHAIN REACTION; PREGNANCY; PREMATURE LABOR; PREVALENCE; PREVENTIVE MEDICINE; RISK FACTOR; STILLBIRTH; UGANDA; ADOLESCENT; ANALYSIS OF VARIANCE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEALTH CARE DELIVERY; MALARIA, FALCIPARUM; NEWBORN; PARASITOLOGY; PLASMODIUM FALCIPARUM; PREGNANCY COMPLICATIONS, PARASITIC; PREMATURITY; PRENATAL CARE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIMALARIALS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREMATURE BIRTH; PRENATAL CARE; PREVALENCE; UGANDA; YOUNG ADULT;

EID: 84942415297     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0909-7     Document Type: Article

References (47)

1. Desai M, ter Kuile FO, Nosten F, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93-104.
2. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007;7:105-17.
3. Mockenhaupt FP, Bedu-Addo G, von Gaertner C, Boyé R, Fricke K, Hannibal I, et al. Detection and clinical manifestation of placental malaria in southern Ghana. Malar J. 2006;5:119.
4. Mockenhaupt FP, Ulmen U, von Gaertner C, Bedu-Addo G, Bienzle U. Diagnosis of placental malaria. J Clin Microbiol. 2002;40:306-8.
5. van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. Lancet Infect Dis. 2013;13:1029-42.
6. Naidoo I, Roper C. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. Trends Parasitol. 2013;29:505-15.
7. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, Hommerich L, Holmberg V, von Oertzen C, et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis. 2008;198:1545-9.
8. WHO. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva: World Health Organization; 2013. http://www.who.int/malaria/publications/atoz/policy-brief-iptp-sp-policy-recommendation/en/. Accessed 15 July 2015.
9. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309:594-604.
10. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One. 2008;3:e1934.
11. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011;53:224-30.
12. Mosha D, Chilongola J, Ndeserua R, Mwingira F, Genton B. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania. Trop Med Int Health. 2014;19:1048-56.
13. Arinaitwe E, Ades V, Walakira A, Ninsiima B, Mugagga O, Patil TS, et al. Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo. Uganda. PLoS One. 2013;8:e73073.
14. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA. 2009;106:9027-32.
15. Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. PLoS One. 2013;8:e56183.
16. Minja DT, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, et al. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis. 2013;19:1446-54.
17. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380-8.
18. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J. 2010;9:247.
19. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One. 2009;4:e4569.
20. WHO. WHO Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy. Geneva: World Health Organization; 2013. http://www.who.int/malaria/mpac/mpac-sep13-erg-ipt-malaria-pregnancy-report.pdf. Accessed 16 July 2015.
21. Chico RM, Cano J, Ariti C, Collier TJ, Chandramohan D, Roper C, Greenwood B. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. Trop Med Int Health. 2015. doi: 10.1111/tmi.12595. [Epub ahead of print].
22. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroaten synthetase reduces the effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis. 2015;211:1997-2005.
23. Ministry of Health Kampala, Uganda: Uganda Clinical Guidelines. Box 7272, 405 Kampala, Uganda 2010. http://apps.who.int/medicinedocs/documents/s21741en/s21741en.pdf. Accessed 23 Sept 2015.
24. Mbonye AK, Birungi J, Yanow SK, Shokoples S, Malamba S, Alifrangis M, et al. The prevalence of P. falciparum resistance markers to sulphadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment of malaria in Uganda. Antimicrob Agents Chemother. 2015;59:5475-82.
25. Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One. 2010;5:e13438.
26. Cox J, Craig M, Le Sueur D, Sharp B. Mapping malaria risk in the highlands of Africa. MARA/HIMAL. Technical report. 1999. https://idl-bnc.idrc.ca/dspace/bitstream/10625/31899/1/117291.pdf. Accessed 16 July 2015.
27. Uganda Bureau of Statistics (UBOS) and ICF International. Uganda Malaria Indicator Survey 2014-15: key indicators. 2015. Kampala, Uganda, and Rockville, Maryland, USA: UBOS and ICF International. http://dhsprogram.com/pubs/pdf/PR64/PR64.pdf. Accessed 16 July 2015.
28. Sullivan KM, Mei Z, Grummer-Strawn L, Parvanta I. Haemoglobin adjustments to define anaemia. Trop Med Int Health. 2008;13:1267-71.
29. Finnstrom O. Studies on maturity in newborn infants. IX. Further observations on the use of external characteristics in estimating gestational age. Acta Paediatr Scand. 1977;66:601-4.
30. Rubio JM, Post RJ, van Leeuwen WM, Henry MC, Lindergard G, Hommel M. Alternative polymerase chain reaction method to identify Plasmodium species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR). Trans R Soc Trop Med Hyg. 2002;96(Suppl 1):S199-204.
31. Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1-8.
32. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007;297:2603-16.
33. Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A, et al. Submicroscopic Plasmodium falciparum infections are associated with maternal anemia, premature births, and low birth weight. Clin Infect Dis. 2015;60:1481-8.
34. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis. 2011;203:464-72.
35. Klement E, Pitché P, Kendjo E, Singo A, D'Almeida S, Akouete F, et al. Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis. 2014;58:651-9.
36. Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, et al. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J. 2009;8:254.
37. Manyando C, Njunju EM, Mwakazanga D, Chongwe G, Mkandawire R, Champo D, et al. Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial. PLoS One. 2014;9:e96017.
38. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
39. Mockenhaupt FP, Bedu-Addo G, Junge C, Hommerich L, Eggelte TA, Bienzle U. Markers of sulfadoxine-pyrimethamine-resistant Plasmodium falciparum in placenta and circulation of pregnant women. Antimicrob Agents Chemother. 2007;51:332-4.
40. Alifrangis M, Nag S, Schousboe ML, Ishengoma D, Lusingu J, Pota H, et al. Independent origin of Plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia. Emerg Infect Dis. 2014;20:1280-6.
41. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012;11:134.
42. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, et al. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg. 2009;80:523-7.
43. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J Infect Dis. 2008;197:1598-604.
44. Zeile I, Gahutu JB, Shyirambere C, Steininger C, Musemakweri A, Sebahungu F, et al. Molecular markers of Plasmodium falciparum drug resistance in southern highland Rwanda. Acta Trop. 2012;121:50-4.
45. Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, et al. Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J. 2010;9:338.
46. González R, Mombo-Ngoma G, Ouédraogo S, Kakolwa MA, Abdulla S, Accrombessi M, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med. 2014;11:e1001733.
47. Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. PLoS One. 2010;5:e14425.